menu
    • menu
    [{"orgOrder":0,"company":"CKD Bio Corporation","sponsor":"Healis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"CKDB-501","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"CKD Bio Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"CKD Bio Corporation \/ Healis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"CKD Bio Corporation \/ Healis Therapeutics"},{"orgOrder":0,"company":"CKD Bio Corporation","sponsor":"Healis Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Serotype A Botulinum Toxin","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"CKD Bio Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CKD Bio Corporation \/ Healis Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"CKD Bio Corporation \/ Healis Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by CKD Bio Corporation

    Menu

    CKD Bio Corporation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CKD Bio Corporation

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            CKD Bio Corporation

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Serotype A Botulinum Toxin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Healis Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Healis Therapeutics Shares Phase III Topline Results for CKDB-501A Glabellar Injections

                            Details : CKDB-501A (serotype A botulinum toxin) is a novel BoNT/A neuromodulator protein. It is being evaluated for the treatment of moderate-to-severe glabellar lines.

                            Brand Name : CKDB-501A

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 27, 2024

                            Lead Product(s) : Serotype A Botulinum Toxin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Healis Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CKD Bio Corporation

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            CKD Bio Corporation

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CKDB-501

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Sponsor : Healis Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Healis Announces Supply Agreement With CKD Bio To Develop CKDB-501

                            Details : Under the agreement, Healis intends to develop CKDB-501, a neuromodulator Serotype A botulinum toxin (BoNT/A) protein, for Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD).

                            Brand Name : CKDB-501

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 02, 2024

                            Lead Product(s) : CKDB-501

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Sponsor : Healis Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth